265 related articles for article (PubMed ID: 18437860)
1. [Conservative treatment of coronary heart disease--current options].
Desch S; Schuler G; Niebauer J
MMW Fortschr Med; 2005 Feb; 147(8):45-7. PubMed ID: 18437860
[TBL] [Abstract][Full Text] [Related]
2. [Secondary prevention of coronary heart disease].
von Schacky C
MMW Fortschr Med; 2003 Mar; 145(13):28, 30, 32-3. PubMed ID: 15101529
[TBL] [Abstract][Full Text] [Related]
3. [Secondary prevention of coronary heart disease. How effective are modern therapy methods?].
Kolenda KD
Dtsch Med Wochenschr; 2003 Sep; 128(36):1849-53. PubMed ID: 12964107
[No Abstract] [Full Text] [Related]
4. Secondary prevention of coronary artery disease.
Hall SL; Lorenc T
Am Fam Physician; 2010 Feb; 81(3):289-96. PubMed ID: 20112887
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapy.
Jaumdally R; Lip GY; Varma C
Int J Clin Pract; 2005 Sep; 59(9):1070-81. PubMed ID: 16115184
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy in patients with stable coronary artery disease treated on an outpatient basis in Poland. Results of the multicentre RECENT study.
Banasiak W; Wilkins A; Pociupany R; Ponikowski P
Kardiol Pol; 2008 Jun; 66(6):642-9; discussion 650. PubMed ID: 18626833
[TBL] [Abstract][Full Text] [Related]
7. [Choosing the right medication for the right patient].
Durand E; Kadri Z; Danchin N
Rev Prat; 2005 Oct; 55(16):1805-11. PubMed ID: 16363431
[TBL] [Abstract][Full Text] [Related]
8. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years.
Robinson JG; Maheshwari N
Am J Cardiol; 2005 Feb; 95(3):373-8. PubMed ID: 15670547
[TBL] [Abstract][Full Text] [Related]
9. Secondary prevention of ischaemic cardiac events.
Gami A
Clin Evid; 2006 Jun; (15):195-228. PubMed ID: 16973010
[No Abstract] [Full Text] [Related]
10. Secondary prevention of coronary heart disease in elderly patients.
Hanna IR; Wenger NK
Am Fam Physician; 2005 Jun; 71(12):2289-96. PubMed ID: 15999866
[TBL] [Abstract][Full Text] [Related]
11. Implementation of evidence based cardiovascular risk treatments by general practitioners.
Crossen K; Scott RS; McGeoch GR; George PM
N Z Med J; 2001 Jun; 114(1133):260-2. PubMed ID: 11453347
[TBL] [Abstract][Full Text] [Related]
12. Preventive maintenance of the aging heart.
Miller M; Gottlieb SO
Geriatrics; 1991 Jul; 46(7):22-30. PubMed ID: 2060800
[TBL] [Abstract][Full Text] [Related]
13. [The secondary prevention of coronary disease: ACE inhibitors, adrenergic beta-blockers and statins for everyone? The arguments con].
Simões L; Guimarães J; Fontes JP
Rev Port Cardiol; 2000 Jan; 19(1):107-13. PubMed ID: 10731796
[No Abstract] [Full Text] [Related]
14. [Secondary prevention after myocardial infarction].
Czuriga I
Orv Hetil; 2002 Sep; 143(37):2117-28. PubMed ID: 12434627
[TBL] [Abstract][Full Text] [Related]
15. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
16. Effect of an ongoing educational program on the use of antiplatelet drugs, beta-blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs in patients with coronary artery disease seen in an academic cardiology clinic.
Nayak D; Aronow WS
Cardiol Rev; 2005; 13(2):95-7. PubMed ID: 15705260
[TBL] [Abstract][Full Text] [Related]
17. Regional variation in medication following coronary events in Germany.
Müller-Nordhorn J; Kulig M; Binting S; Völler H; Krobot KJ; Willich SN
Int J Cardiol; 2005 Jun; 102(1):47-53. PubMed ID: 15939098
[TBL] [Abstract][Full Text] [Related]
18. Benefits of risk factor modification through cardiac rehabilitation.
Borrás IC; Cruz-Jiménez M; Nadal E; Middelhoff A; Rivera A
Bol Asoc Med P R; 2008; 100(4):75-9. PubMed ID: 19400532
[TBL] [Abstract][Full Text] [Related]
19. [Secondary prevention after an acute myocardial infarct. Adrenergic beta-blockers, angiotensin-converting enzyme inhibitors and statins for everyone?].
Morais J
Rev Port Cardiol; 2000 Jan; 19(1):99-105. PubMed ID: 10731795
[No Abstract] [Full Text] [Related]
20. Secondary prevention of CHD.
Nelson MR; Tonkin A
Aust Fam Physician; 2005 Jun; 34(6):433-40. PubMed ID: 15931401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
